Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity
Systemic delivery of peptide-major histocompatibility complex (pMHC) class II-based nanomedicines can re-program cognate autoantigen-experienced CD4+ T cells into disease-suppressing T-regulatory type 1 (TR1)-like cells. In turn, these TR1-like cells trigger the formation of complex regulatory cell...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.684240/full |
| _version_ | 1818649273808453632 |
|---|---|
| author | Patricia Solé Pere Santamaria Pere Santamaria |
| author_facet | Patricia Solé Pere Santamaria Pere Santamaria |
| author_sort | Patricia Solé |
| collection | DOAJ |
| description | Systemic delivery of peptide-major histocompatibility complex (pMHC) class II-based nanomedicines can re-program cognate autoantigen-experienced CD4+ T cells into disease-suppressing T-regulatory type 1 (TR1)-like cells. In turn, these TR1-like cells trigger the formation of complex regulatory cell networks that can effectively suppress organ-specific autoimmunity without impairing normal immunity. In this review, we summarize our current understanding of the transcriptional, phenotypic and functional make up of TR1-like cells as described in the literature. The true identity and direct precursors of these cells remain unclear, in particular whether TR1-like cells comprise a single terminally-differentiated lymphocyte population with distinct transcriptional and epigenetic features, or a collection of phenotypically different subsets sharing key regulatory properties. We propose that detailed transcriptional and epigenetic characterization of homogeneous pools of TR1-like cells will unravel this conundrum. |
| first_indexed | 2024-12-17T01:31:42Z |
| format | Article |
| id | doaj.art-c20ea1c67f46474ea512615958d705d8 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-17T01:31:42Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c20ea1c67f46474ea512615958d705d82022-12-21T22:08:33ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-07-011210.3389/fimmu.2021.684240684240Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of AutoimmunityPatricia Solé0Pere Santamaria1Pere Santamaria2Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, SpainInstitut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, SpainJulia McFarlane Diabetes Research Centre (JMDRC) and Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaSystemic delivery of peptide-major histocompatibility complex (pMHC) class II-based nanomedicines can re-program cognate autoantigen-experienced CD4+ T cells into disease-suppressing T-regulatory type 1 (TR1)-like cells. In turn, these TR1-like cells trigger the formation of complex regulatory cell networks that can effectively suppress organ-specific autoimmunity without impairing normal immunity. In this review, we summarize our current understanding of the transcriptional, phenotypic and functional make up of TR1-like cells as described in the literature. The true identity and direct precursors of these cells remain unclear, in particular whether TR1-like cells comprise a single terminally-differentiated lymphocyte population with distinct transcriptional and epigenetic features, or a collection of phenotypically different subsets sharing key regulatory properties. We propose that detailed transcriptional and epigenetic characterization of homogeneous pools of TR1-like cells will unravel this conundrum.https://www.frontiersin.org/articles/10.3389/fimmu.2021.684240/fullT-regulatory type 1 (TR1) cellspeptide-MHC class II-coated nanoparticlesT-cell reprogramminginterleukin 10 (IL10)autoimmune diseasetherapy |
| spellingShingle | Patricia Solé Pere Santamaria Pere Santamaria Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity Frontiers in Immunology T-regulatory type 1 (TR1) cells peptide-MHC class II-coated nanoparticles T-cell reprogramming interleukin 10 (IL10) autoimmune disease therapy |
| title | Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity |
| title_full | Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity |
| title_fullStr | Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity |
| title_full_unstemmed | Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity |
| title_short | Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity |
| title_sort | re programming autoreactive t cells into t regulatory type 1 cells for the treatment of autoimmunity |
| topic | T-regulatory type 1 (TR1) cells peptide-MHC class II-coated nanoparticles T-cell reprogramming interleukin 10 (IL10) autoimmune disease therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.684240/full |
| work_keys_str_mv | AT patriciasole reprogrammingautoreactivetcellsintotregulatorytype1cellsforthetreatmentofautoimmunity AT peresantamaria reprogrammingautoreactivetcellsintotregulatorytype1cellsforthetreatmentofautoimmunity AT peresantamaria reprogrammingautoreactivetcellsintotregulatorytype1cellsforthetreatmentofautoimmunity |